📣 VC round data is live. Check it out!
- Public Comps
- Emyria
Emyria Valuation Multiples
Discover revenue and EBITDA valuation multiples for Emyria and similar public comparables like Gesundheitswelt Chiemgau, Maternus-Kliniken, Clinica de Marly, Concord Medical Services and more.
Emyria Overview
About Emyria
Emyria Ltd operates a network of specialist medical clinics and uses purpose-built software and technology to gather clinical data from consenting patients. It operates in one segment of research and development.
Founded
2018
HQ

Employees
N/A
Website
Sectors
Financials (FY)
EV
$16M
Valuation Multiples
Start free trialEmyria Financials
Emyria reported last fiscal year revenue of $936K and negative EBITDA of ($2M).
In the same fiscal year, Emyria generated ($44K) in gross profit, ($2M) in EBITDA losses, and had net loss of ($2M).
Emyria P&L
In the most recent fiscal year, Emyria reported revenue of $936K and EBITDA of ($2M).
Emyria is unprofitable as of last fiscal year, with gross margin of (5%), EBITDA margin of (194%), and net margin of (240%).
Financial data powered by Morningstar, Inc.
Emyria Stock Performance
Emyria has current market cap of $23M, and enterprise value of $16M.
Emyria's stock price is $0.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16M | $23M | 3.0% | — | — | — | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEmyria Valuation Multiples
Emyria trades at 17.0x EV/Revenue multiple, and (8.8x) EV/EBITDA.
Emyria Financial Valuation Multiples
As of May 23, 2026, Emyria has market cap of $23M and EV of $16M.
Emyria has a P/E ratio of (10.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Emyria Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Emyria Margins & Growth Rates
Emyria grew revenue by 212% and EBITDA by 104% in the last fiscal year.
In the most recent fiscal year, Emyria reported gross margin of (5%), EBITDA margin of (194%), and net margin of (240%).
Emyria Margins
Emyria Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Emyria Operational KPIs
Emyria's Rule of 40 is 65% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Emyria's Rule of X is 297% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Emyria Competitors
Emyria competitors include Gesundheitswelt Chiemgau, Maternus-Kliniken, Clinica de Marly, Concord Medical Services, Eukedos, MedNation, Speed Medical SAE, Sudmedica, Latvijas Juras medicinas and Amwill Healthcare.
Most Emyria public comparables operate across Hospitals & Clinics.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.5x | — | 4.5x | — | |||
| 1.7x | — | 18.6x | — | |||
| — | — | — | — | |||
| 7.6x | — | (48.5x) | — | |||
| 2.7x | — | 12.8x | — | |||
| 0.4x | — | 3.6x | — | |||
| — | — | — | — | |||
| 198.8x | — | (113.1x) | — | |||
This data is available for Pro users. Sign up to see all Emyria competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Emyria
| When was Emyria founded? | Emyria was founded in 2018. |
| Where is Emyria headquartered? | Emyria is headquartered in Australia. |
| Is Emyria publicly listed? | Yes, Emyria is a public company listed on Frankfurt Stock Exchange. |
| What is the stock symbol of Emyria? | Emyria trades under Q84 ticker. |
| When did Emyria go public? | Emyria went public in 2020. |
| Who are competitors of Emyria? | Emyria main competitors include Gesundheitswelt Chiemgau, Maternus-Kliniken, Clinica de Marly, Concord Medical Services, Eukedos, MedNation, Speed Medical SAE, Sudmedica, Latvijas Juras medicinas, Amwill Healthcare. |
| What is the current market cap of Emyria? | Emyria's current market cap is $23M. |
| What is the current revenue of Emyria? | Emyria's last fiscal year revenue is $936K. |
| What is the current revenue growth of Emyria? | Emyria revenue growth (vs. last FY) is 212%. |
| What is the current EV/Revenue multiple of Emyria? | Current revenue multiple of Emyria is 17.0x. |
| Is Emyria profitable? | No, Emyria is not profitable. |
| How many companies Emyria has acquired to date? | Emyria hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Emyria has invested to date? | Emyria hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Emyria
Lists including Emyria
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.